Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.31.

Several equities research analysts have recently commented on TRVI shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday, December 12th. B. Riley reaffirmed a "buy" rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. HC Wainwright boosted their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a "buy" rating in a report on Thursday, December 12th. Leerink Partnrs upgraded Trevi Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. Finally, Leerink Partners began coverage on Trevi Therapeutics in a research report on Monday, September 9th. They issued an "outperform" rating and a $7.00 price target for the company.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRVI. JPMorgan Chase & Co. lifted its holdings in Trevi Therapeutics by 220.6% in the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company's stock valued at $336,000 after acquiring an additional 69,167 shares during the period. Barclays PLC lifted its stake in shares of Trevi Therapeutics by 180.8% in the 3rd quarter. Barclays PLC now owns 95,232 shares of the company's stock worth $319,000 after purchasing an additional 61,317 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company's stock worth $4,223,000 after buying an additional 117,418 shares during the last quarter. State Street Corp boosted its holdings in shares of Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company's stock worth $3,183,000 after buying an additional 53,051 shares during the last quarter. Finally, Fred Alger Management LLC bought a new stake in Trevi Therapeutics during the third quarter valued at approximately $256,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI traded up $0.24 during midday trading on Thursday, reaching $4.36. 1,338,546 shares of the stock traded hands, compared to its average volume of 616,702. The stock has a market capitalization of $335.14 million, a P/E ratio of -9.91 and a beta of 0.96. The company has a fifty day moving average of $3.28 and a 200 day moving average of $3.08. Trevi Therapeutics has a 12 month low of $1.27 and a 12 month high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). During the same period in the prior year, the firm posted ($0.08) EPS. On average, analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.